IL102703A - N-sulfonyl indoline derivatives carrying an amide functional group, their preparation and pharmaceutical compositions containing them - Google Patents

N-sulfonyl indoline derivatives carrying an amide functional group, their preparation and pharmaceutical compositions containing them

Info

Publication number
IL102703A
IL102703A IL102703A IL10270392A IL102703A IL 102703 A IL102703 A IL 102703A IL 102703 A IL102703 A IL 102703A IL 10270392 A IL10270392 A IL 10270392A IL 102703 A IL102703 A IL 102703A
Authority
IL
Israel
Prior art keywords
group
substituted
alkyl
alkyls
free
Prior art date
Application number
IL102703A
Other versions
IL102703A0 (en
Original Assignee
Sanofi Elf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Elf filed Critical Sanofi Elf
Priority to IL11759292A priority Critical patent/IL117592A/en
Publication of IL102703A0 publication Critical patent/IL102703A0/en
Publication of IL102703A publication Critical patent/IL102703A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Compounds with affinity for the vasopressin and ocytocin receptors of the formula R2OH R3R4N (R1)nSO2 (CH2)m R5 in which R1 is a halogen atom, a C1-C4 alkyl, a hydroxyl, a C1-C4 alkoxy, a benzyloxy group, a cyano group, a trifluoromethyl group, nitro group or an amino group; R2 is a C1-C6 alkyl, a C3-C7 cycloalkyl, a C5-C7 cycloalkene or a phenyl which is unsubstituted or monosubstituted or polysubstituted by a C1-C4 alkyl, a C1-C4 alkoxy, a halogen, a trifluoromethyl group or an amino group, or R2 is a nitrophenyl which is unsubstituted or monosubstituted by a trifluoromethyl group or monosubstituted or polysubstituted by a C1-C4 alkyl or a halogen; R3 is a hydrogen atom; R4 is a carbamoyl group of formula CONR6R7; R5 is a C1-C4 alkyl; a l-naphthyl; a 2-naphthyl; a 5-dimethylamino-1-naphthyl; a phenyl which is un-substituted or substituted by one or more substituents selected from a halogen atom, a C1-C4 alkyl, a trifluoromethyl group, an amino group which is free or substituted by one or 2 C1-C4 alkyls, a hydroxyl, a C1-C4 alkoxy, a C2-C4 alkenoxy, a C1-C4 alkylthio, a trifluoromethoxy group, a benzyloxy group, a cyano group, a carboxyl group, a C1-C4 alkoxycarbonyl group, a carbamoyl group which is free or substituted by one or two C1-C4 alkyls or a C1-C4 alkylamido group, or R5 is a nitrophenyl which is unsubstituted or monosubstituted by a trifluoromethyl group or a C2-C4 alkenoxy or mono- or poly- substituted by a halogen, a C1-C4 alkyl, a C1-C4 alkoxy, a C1-C4 alkylthio, a trifluoromethoxy group or a benzyloxy group; R6 is a C1-C6 alkyl or R6 is similar to R7; R7 is a 4-piperidyl group or a 3-azetidinyl group, the said groups being substituted or unsubstituted on the nitrogen by a C1-C4 alkyl, by a benzyloxy-carbonyl or by a C1-C4 alkoxycarbonyl; a group (CH2)r which is itself substituted by a phenyl group, a 2-, 3- or 4-pyridyl group, by a hydroxyl group or by an amino group which is free or substituted by one or two C1-C4 alkyls, a carboxyl group, a C1-C4 alkoxycarbonyl group, a benzyloxycarbonyl group or a carbamoyl group which is free or substituted by one or 2 C1-C4 alkyls; or R6 and R7 together, with the nitrogen atom to which they are connected, form a heterocycle selected from: morpholine, thiomorpholine, thiazolidine or 2, 2-dimethylthiazolidine, unsubstituted or substituted by R8, piperazine, unsubstituted or substituted at the 4-position by a group R"8, an unsaturated, 5-membered ring containing a single nitrogen atom and substituted by R8 or a saturated, 3-, 4-, 5-, 6- or 7-membered ring containing a single nitrogen atom and substituted by R8 and R9; or an azetidinyl group substituted by a t-butoxy-carbonyl group; R8 is R(8 or a group (CH2)r which is itself substituted by a hydroxyl or by an amino which is free or substituted by one or two C1-C4 alkyls; R(8 is a group (CH2)q which is itself substituted by a carboxyl group, a C1-C4 alkoxycarbonyl group, a benzyloxycarbonyl group, a carbamoyl group which is free or substituted by a hydroxyl or by one or two C1-C4 alkyls or an aminocarbothioyl group which is free or substituted by one or two C1-C4 alkyls; R"8 is R(8 or a group (CH2)2NH2, which is free or substituted by one or two C1-C4 alkyls or a methyl group; R9 is hydrogen, a halogen, a group (CH2)rOR10, a group (CH2)rNR11R12, a group (CH2)5CONR11R(11 or an azido group; R10 is hydrogen, a C1-C4 alkyl, a mesyl or a tosyl; R11, R(11 and R12 are each a hydrogen or a C1-C4 alkyl or R11 is hydrogen or methyl and R12 is a benzyloxycarbonyl or a C1-C4 alkoxycarbonyl; n is 0, 1 or 2; m is 0, 1 or 2; q is 0, 1, 2 or 3; r is 0, 1, 2 or 3, with the limitation that r is not zero when R8 or R9 is at the alpha- position of the intracyclic amide nitrogen; s is 0 or 1; as well as their possible salts.
IL102703A 1991-08-02 1992-07-31 N-sulfonyl indoline derivatives carrying an amide functional group, their preparation and pharmaceutical compositions containing them IL102703A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL11759292A IL117592A (en) 1991-08-02 1992-07-31 N-substituted sulfonamidobenzene compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9109908A FR2679903B1 (en) 1991-08-02 1991-08-02 DERIVATIVES OF N-SULFONYL INDOLINE CARRYING AN AMIDIC FUNCTION, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.

Publications (2)

Publication Number Publication Date
IL102703A0 IL102703A0 (en) 1993-01-14
IL102703A true IL102703A (en) 1997-03-18

Family

ID=9415909

Family Applications (3)

Application Number Title Priority Date Filing Date
IL102703A IL102703A (en) 1991-08-02 1992-07-31 N-sulfonyl indoline derivatives carrying an amide functional group, their preparation and pharmaceutical compositions containing them
IL11759292A IL117592A (en) 1991-08-02 1992-07-31 N-substituted sulfonamidobenzene compounds
IL11759296A IL117592A0 (en) 1991-08-02 1996-03-21 N-substituted sulfonamidobenzene compounds

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL11759292A IL117592A (en) 1991-08-02 1992-07-31 N-substituted sulfonamidobenzene compounds
IL11759296A IL117592A0 (en) 1991-08-02 1996-03-21 N-substituted sulfonamidobenzene compounds

Country Status (29)

Country Link
EP (1) EP0526348B1 (en)
JP (1) JP2633085B2 (en)
KR (1) KR100241583B1 (en)
AT (1) ATE163289T1 (en)
AU (2) AU658664B2 (en)
BR (1) BR9205336A (en)
CA (2) CA2093221C (en)
CZ (1) CZ288173B6 (en)
DE (1) DE69224450T2 (en)
DK (1) DK0526348T3 (en)
ES (1) ES2117038T3 (en)
FI (2) FI104069B (en)
FR (1) FR2679903B1 (en)
HK (1) HK1008741A1 (en)
HU (2) HUT68927A (en)
IL (3) IL102703A (en)
LT (1) LT3064B (en)
LV (1) LV10091B (en)
MX (1) MX9204487A (en)
MY (1) MY110517A (en)
NO (1) NO180047C (en)
NZ (1) NZ243795A (en)
PH (1) PH30661A (en)
RU (1) RU2104268C1 (en)
SG (1) SG47501A1 (en)
SK (1) SK283463B6 (en)
UA (1) UA27238C2 (en)
WO (1) WO1993003013A1 (en)
ZA (1) ZA925781B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665441B1 (en) * 1990-07-31 1992-12-04 Sanofi Sa N-SULFONYL INDOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
FR2708608B1 (en) * 1993-07-30 1995-10-27 Sanofi Sa N-sulfonylbenzimidazolone derivatives, their preparation, pharmaceutical compositions containing them.
FR2756736B1 (en) * 1996-12-05 1999-03-05 Sanofi Sa PHARMACEUTICAL COMPOSITIONS CONTAINING N-SULFONYL INDOLINE DERIVATIVES
US7030114B1 (en) 1997-07-31 2006-04-18 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6583139B1 (en) 1997-07-31 2003-06-24 Eugene D. Thorsett Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6362341B1 (en) 1997-07-31 2002-03-26 Athena Neurosciences, Inc. Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4
BR9811569A (en) * 1997-07-31 2000-09-19 Elan Pharm Inc Compounds that inhibit vla-4-mediated leukocyte adhesion
PL338373A1 (en) * 1997-07-31 2000-10-23 Elan Pharm Inc Dipeptide and its affinite compounds inhibiting adhesion of leucocytes occurring through mediation of vla-4
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6291453B1 (en) 1997-07-31 2001-09-18 Athena Neurosciences, Inc. 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
US6489300B1 (en) 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
BR9811594A (en) * 1997-07-31 2000-09-05 Elan Pharm Inc Sulphonylated dipeptide compounds that inhibit vla-4 mediated leukocyte adhesion
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
US6423688B1 (en) 1997-07-31 2002-07-23 Athena Neurosciences, Inc. Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4
US6559127B1 (en) 1997-07-31 2003-05-06 Athena Neurosciences, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
FR2775598A1 (en) 1998-03-06 1999-09-10 Sanofi Sa PHARMACEUTICAL COMPOSITIONS COMPRISING A SELECTIVE ANTAGONIST OF ARGININE-VASOPRESSIN V1A RECEPTORS AND A SELECTIVE ANTAGONIST OF ARGININE-VASOPRESSIN V2 RECEPTORS
FR2778103A1 (en) * 1998-04-29 1999-11-05 Sanofi Sa PHARMACEUTICAL COMPOSITIONS CONTAINING IN ASSOCIATION A V1A ARGININE-VASOPRESSIN ANTAGONIST AND AN ANGIOTENSIN II AT1 RECEPTOR ANTAGONIST
FR2786486B3 (en) * 1998-11-16 2000-12-08 Sanofi Sa PROCESS FOR THE PREPARATION OF (2S) -1 - [(2R, 3S) -5-CHLORO-3- (2- CHLOROPHENYL) -1- (3,4-DIMETHOXY BENZENESULFONYL) -3-HYDROXY- 2,3-DIHYDRO- 1H-INDOLE-2-CARBONYL] PYRROLIDINE-2-CARBOXAMIDE, ITS SOLVATES AND / OR HYDRATES
CA2359115C (en) 1999-01-22 2011-06-21 Elan Pharmaceuticals, Inc. Acyl derivatives which treat vla-4 related disorders
AR035476A1 (en) 1999-01-22 2004-06-02 Elan Pharm Inc HETEROARILO AND HETEROCICLIC COMPOUNDS WITH FUSIONED RING, WHICH INHIBIT THE ADHESION OF LEUKOCYTES THROUGH VLA-4, PHARMACEUTICAL COMPOSITIONS, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND A BIOLOGICAL METHOD 4
CA2359114A1 (en) * 1999-01-25 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6407066B1 (en) 1999-01-26 2002-06-18 Elan Pharmaceuticals, Inc. Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4
FR2792834A1 (en) * 1999-04-29 2000-11-03 Sanofi Sa USE OF SR 49059, ITS PHARMACEUTICALLY ACCEPTABLE SOLVATES AND / OR HYDATES FOR THE PREPARATION OF MEDICINES USEFUL IN THE TREATMENT OR PREVENTION OF RAYNAUD PHENOMENON
FR2805536B1 (en) * 2000-02-25 2002-08-23 Sanofi Synthelabo NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2805992A1 (en) * 2000-03-08 2001-09-14 Sanofi Synthelabo Oral administration of N-sulfonyl-indoline derivative to treat central nervous system, cardiovascular or gastric disorders, using polyethylene glycol, polysorbate and poloxamer as solubilizers for high bioavailability
AU1401902A (en) 2000-10-17 2002-04-29 Applied Research Systems Pharmaceutically active sulfanilide derivatives
WO2002044179A1 (en) 2000-11-28 2002-06-06 Yamanouchi Pharmaceutical Co., Ltd. 1,4,5,6-tetrahydroimidazo[4,5-d]diazepine derivatives or salts thereof
JP4044740B2 (en) * 2001-05-31 2008-02-06 信越化学工業株式会社 Resist material and pattern forming method
DK1458381T3 (en) 2001-12-20 2006-03-20 Applied Research Systems Triazoles as oxytocin antagonists
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
CA2498091C (en) * 2002-10-11 2011-03-22 Actelion Pharmaceuticals Ltd. Sulfonylamino-acetic acid derivatives
AU2003298661B2 (en) 2002-11-18 2007-05-10 Chemocentryx, Inc. Aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
DK1940826T3 (en) 2005-09-29 2011-04-18 Elan Pharm Inc Pyrimidinylamide compounds that inhibit leukocyte adhesion mediated through BLA-4
EP1940827B1 (en) 2005-09-29 2011-03-16 Elan Pharmaceuticals Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
JP5135235B2 (en) 2006-02-27 2013-02-06 エラン ファーマシューティカルズ，インコーポレイテッド Pyrimidinylsulfonamide compounds that inhibit leukocyte adhesion mediated by VAL-4
WO2010126914A1 (en) 2009-04-27 2010-11-04 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins
TW201938171A (en) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 Tricyclic compounds as vasopressin V1a receptor antagonists
HU231206B1 (en) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3838167A (en) * 1972-08-01 1974-09-24 Lilly Co Eli Process for preparing indoles
US4479963A (en) * 1981-02-17 1984-10-30 Ciba-Geigy Corporation 1-Carboxyalkanoylindoline-2-carboxylic acids
DE3705934A1 (en) * 1987-02-25 1988-09-08 Nattermann A & Cie Indolyl derivatives, processes for their preparation, and their use as medicaments
FR2665441B1 (en) * 1990-07-31 1992-12-04 Sanofi Sa N-SULFONYL INDOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.

Also Published As

Publication number Publication date
IL102703A0 (en) 1993-01-14
KR100241583B1 (en) 2000-03-02
UA27238C2 (en) 2000-08-15
CA2093221A1 (en) 1993-02-03
FI980175A0 (en) 1998-01-27
MY110517A (en) 1998-07-31
NO180047B (en) 1996-10-28
LV10091B (en) 1995-04-20
DK0526348T3 (en) 1998-11-23
EP0526348A1 (en) 1993-02-03
DE69224450D1 (en) 1998-03-26
CA2206776C (en) 2002-02-26
DE69224450T2 (en) 1998-07-30
NZ243795A (en) 1995-04-27
FI931476A0 (en) 1993-04-01
IL117592A (en) 1999-04-11
JP2633085B2 (en) 1997-07-23
NO180047C (en) 1997-02-05
AU2475892A (en) 1993-03-02
FI104069B1 (en) 1999-11-15
CA2093221C (en) 1998-09-22
FI104069B (en) 1999-11-15
PH30661A (en) 1997-09-16
MX9204487A (en) 1993-02-01
HU211884A9 (en) 1995-12-28
ES2117038T3 (en) 1998-08-01
FI107048B (en) 2001-05-31
SK283463B6 (en) 2003-08-05
SK42693A3 (en) 1993-10-06
IL117592A0 (en) 1996-07-23
CZ68293A3 (en) 1994-01-19
WO1993003013A1 (en) 1993-02-18
FR2679903A1 (en) 1993-02-05
HK1008741A1 (en) 1999-05-14
LV10091A (en) 1994-05-10
CA2206776A1 (en) 1993-02-03
HUT68927A (en) 1995-08-28
RU2104268C1 (en) 1998-02-10
LT3064B (en) 1994-10-25
FR2679903B1 (en) 1993-12-03
NO931262D0 (en) 1993-04-01
NO931262L (en) 1993-05-26
CZ288173B6 (en) 2001-05-16
AU658664B2 (en) 1995-04-27
HU9300951D0 (en) 1993-06-28
JPH06501960A (en) 1994-03-03
ATE163289T1 (en) 1998-03-15
FI980175A (en) 1998-01-27
BR9205336A (en) 1993-11-16
LTIP114A (en) 1994-06-15
FI931476A (en) 1993-04-01
EP0526348B1 (en) 1998-02-18
ZA925781B (en) 1993-03-02
AU691223B2 (en) 1998-05-14
SG47501A1 (en) 1998-04-17
AU1154195A (en) 1995-05-04

Similar Documents

Publication Publication Date Title
IL102703A (en) N-sulfonyl indoline derivatives carrying an amide functional group, their preparation and pharmaceutical compositions containing them
NZ331319A (en) Cyclic amine derivatives that are CCR-3 receptor (chemokine receptor) antagonists, compositions containing them and methods for their use (to combat eosinophil induced diseases).
TR200400185T4 (en) As inhibitors of PDE 5, 8-quinolinecanthine and 8-isoquinolinecanthine derivatives.
AR024969A1 (en) DERIVATIVES OF 8-PHENYL-6,9-DIHIDRO- [1,2,4] TRIAZOL [3,4-I] PURIN-5-ONA
TR200003598T2 (en) Amide derivatives and nociceptin antagonists
HUP0202799A2 (en) Herbicidal isoxazoline derivatives and composition containing the same
DE69525355D1 (en) 1-ACYL-4-ALIPHATIC AMINOPIPERIDINE COMPOUNDS
ES482134A1 (en) 1-(3-Mercapto-2-methylpropanoyl)prolyl amino acid derivatives and salts thereof, processes for their preparation, and pharmaceutical compositions containing such compounds.
IE41539L (en) Chroman derivatives.
HUP9902410A2 (en) Amidino derivatives, preparation and use as thrombin inhibitors thereof, pharmaceutical compositions containing these compounds
EP0096517A3 (en) Aryl pyrazinones
IL99012A0 (en) N-sulfonylindoline derivatives,their preparation and pharmaceutical compositions containing them
SE8101464L (en) 2-PENEM-3-CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND USE
DE69319925D1 (en) INDOL PIPERAZINE DERIVATIVES AS SELECTIVE LIGANDS OF THE 5HT1D AND 5HT1B RECEPTORS CAN BE USED AS MEDICINAL PRODUCTS
ATE166055T1 (en) 5H,10H-IMIDAZO(1,2-A>INDENO(1,2-E>PYRAZINE-4-ONE DERIVATIVES, THEIR PRODUCTION AND THE MEDICINAL PRODUCTS CONTAINING THEM
ES417638A1 (en) 2,4,5-trisubstituted oxazoles
DE69104475D1 (en) UREA DERIVATIVES, THEIR PRODUCTION AND THEIR MEDICINAL PRODUCTS.
KR930703327A (en) Condensed thiophene compounds and their medical uses
KR930006024A (en) Imidazo indolizine derivatives and preparation method thereof
GB1424492A (en) Pyrazol-5-ones their preparation and their pharmaceutical use
HUP9901290A2 (en) Polyfluoroalyl tryptophan tripeptide thrombin inhibitors
ES8506018A1 (en) Fluoralkylatedcarbapenem derivatives
HUP9702149A2 (en) Heterocyclic substituted piperazinone derivatives as tachykinin receptor antagonists, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds
GB1428626A (en) Trisubstituted 1,2,4-triazoles
ES8306099A1 (en) Amino-acid derivatives, their preparation and their use as pharmaceuticals

Legal Events

Date Code Title Description
FF Patent granted
HP Change in proprietorship
KB Patent renewed
KB Patent renewed
HC Change of name of proprietor(s)
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees